Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3072 - Evaluation of the novel “trial within a trial” design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)


09 Oct 2016


Poster display


Colin Hessel


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


C. Hessel1, M. Mangeshkar1, R.J. Motzer2, B. Escudier3, T.B. Powles4, G. Schwab5, T.K. Choueiri6

Author affiliations

  • 1 Biostatistics, Exelixis, Inc., 94080 - South San Francisco/US
  • 2 Medical Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 3 Medical Oncology, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 4 Department Of Medical Oncology, Barts Cancer Institute-Queen Mary University of London, EC1M 6BQ - London/GB
  • 5 Product Development And Medical Affairs, Exelixis, Inc., 94080 - South San Francisco/US
  • 6 Department Of Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, 02215 - Boston/US


Abstract 3072


Comparative studies of time-to-event endpoints should be designed to yield a wide range of event times to accurately characterize the hazard function (HF) relationship and ensure valid hazard ratio (HR) estimates. The total sample size (N) is ideally small relative to the required number of events. The primary endpoint of progression-free survival (PFS) in METEOR (NCT01865747) required 259 events; the secondary overall survival (OS) endpoint required 408. As a result, the planned total N (650) was much larger than required to evaluate PFS. Shorter PFS times would be overrepresented if an event-driven analysis was conducted among all 650 pts, potentially undermining the ability to assess the proportional hazards assumption. To address this, METEOR employed a novel “trial within a trial” design: PFS was analyzed in the first 375 randomized pts (PFS Pop); OS was analyzed in all 658 randomized pts (ITT Pop). Both populations follow the intention-to-treat principle.


To assess the impact of the design, PFS was reanalyzed at the date of the 247th event in the ITT Pop (minimum follow-up [min f/up] 2 days) and compared to both the primary endpoint results for 247 events in the PFS Pop (min f/up 11 mo) and supportive results for 394 events in the ITT Pop (min f/up 6 mo).


The HFs were reasonably proportional between arms in all analyses. The HR and median estimate for the cabozantinib arm in the primary analysis of 247 events in the PFS Pop (0.58, 7.4 mo) are close to the estimates in the larger analysis of 394 events in the ITT Pop (0.52, 7.4 mo) using the same cutoff date. Despite the similar relationship among HFs, an analysis using an earlier cutoff based upon 247 events in the ITT Pop is biased, overestimating the treatment benefit as represented by the HR and underestimating the median PFS in the cabozantinib arm (0.49, 6 mo).


The “trial within a trial” design provided critical data required to characterize the HF relationship in METEOR and demonstrate robust results. This design should be considered when the HF relationship is unknown and the total N is large relative to the number of events needed for a time-to-event endpoint.

Clinical trial identification


Legal entity responsible for the study

Exelixis, Inc.


Exelixis, Inc.


C. Hessel: Employee: Exelixis Stock or other Ownership: Exelixis. M. Mangeshkar: Employee and Stock Ownership: Exelixis, Inc. R.J. Motzer: Consulting or Advisory Role: Pfizer, Novartis, Eisai Inc. Research Funding: Exelixis, BMS, Novartis, Pfizer, Genentech/Roche. B. Escudier: Honoraria: Exelixis, Novartis, Pfizer, BMS, Roche. T.B. Powles: Honoraria: Genentech/Roche, Novartis Consulting/Advisory Role: Genentech/Roche, BMS Research Funding: AZ/MedImmune, Genentech/Roche, GlaxoSmithKline. G. Schwab: Employee, Stock Ownership, Officer of the Company: Exelixis, Inc. T.K. Choueiri: Consulting/Advisory Role: Pfizer, GSK, Novartis, Merck, Bayer, Eisai, Roche, Prometheus. Labs Inc, BMS, Foundation Medicine Inc. Research Funding: Pfizer, GSK, Novartis, BMS, Merck, Exelixis, Roche, AstraZeneca, Tracon, Peloton.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings